Nucleic acids encoding human telomerase reverse...

Details Nucleic acids encoding human telomerase reverse... Nucleic acids encoding human telomerase reverse...

2007-08-28

2007-08-28

Sisson, Bradley L. (Department: 1634)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S023100, C435S183000, C435S320100, C435S252300

Reexamination Certificate

active

09721506

ABSTRACT:
The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.

REFERENCES:
patent: 3817837 (1974-06-01), Tanenholtz et al.
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 3939350 (1976-02-01), Kronick et al.
patent: 3996345 (1976-12-01), Ullman et al.
patent: 4275149 (1981-06-01), Litman et al.
patent: 4277437 (1981-07-01), Maggio
patent: 4366241 (1982-12-01), Tom et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4965188 (1990-10-01), Mullis et al.
patent: 5489508 (1996-02-01), West et al.
patent: 5583016 (1996-12-01), Villeponteau et al.
patent: 5597697 (1997-01-01), Diamond
patent: 5747317 (1998-05-01), Cao
patent: 5770422 (1998-06-01), Collins
patent: 5917025 (1999-06-01), Collins
patent: 6093809 (2000-07-01), Cech et al.
patent: 6166178 (2000-12-01), Cech et al.
patent: 6258535 (2001-07-01), Villeponteau et al.
patent: 6261556 (2001-07-01), Weinrich et al.
patent: 6261836 (2001-07-01), Cech et al.
patent: 6309867 (2001-10-01), Cech et al.
patent: 6337200 (2002-01-01), Morin
patent: 6440735 (2002-08-01), Gaeta
patent: 6444650 (2002-09-01), Cech et al.
patent: 6475789 (2002-11-01), Cech et al.
patent: 6517834 (2003-02-01), Weinrich et al.
patent: 6608188 (2003-08-01), Tsuchiya et al.
patent: 6610839 (2003-08-01), Morin et al.
patent: 6617110 (2003-09-01), Cech et al.
patent: 6627619 (2003-09-01), Cech et al.
patent: 6767719 (2004-07-01), Morin et al.
patent: 2002/0164786 (2002-11-01), Cech et al.
patent: 2002/0187471 (2002-12-01), Cech et al.
patent: 2003/0009019 (2003-01-01), Cech et al.
patent: 2003/0032075 (2003-02-01), Cech et al.
patent: 2003/0044953 (2003-03-01), Cech et al.
patent: 2003/0059787 (2003-03-01), Cech et al.
patent: 2003/0096344 (2003-05-01), Cech et al.
patent: 2003/0100093 (2003-05-01), Cech et al.
patent: 2271718 (1998-05-01), None
patent: 2 317 891 (1998-04-01), None
patent: 09154575 (1997-06-01), None
patent: WO84/03564 (1984-09-01), None
patent: WO93/23572 (1993-11-01), None
patent: WO94/17210 (1994-08-01), None
patent: WO95/13362 (1995-05-01), None
patent: WO96/01835 (1996-01-01), None
patent: WO96/12811 (1996-05-01), None
patent: WO96/19580 (1996-08-01), None
patent: WO98/01542 (1998-01-01), None
patent: WO98/01549 (1998-01-01), None
patent: WO98/06938 (1998-02-01), None
patent: WO98/07838 (1998-03-01), None
patent: WO98/14592 (1998-04-01), None
patent: WO98/14593 (1998-04-01), None
patent: WO98/21343 (1998-05-01), None
patent: WO98/23759 (1998-06-01), None
patent: WO98/37181 (1998-08-01), None
patent: WO98/45450 (1998-10-01), None
patent: WO98/40868 (1998-12-01), None
patent: WO98/59040 (1998-12-01), None
patent: WO99/01560 (1999-01-01), None
patent: WO99/33998 (1999-07-01), None
patent: WO99/38964 (1999-08-01), None
patent: WO 00/46355 (2000-08-01), None
Rhyu, “Telomers, Telomerase, and Immortality,” Journal of the National Cancer Institute, Jun. 21, 1995, vol. 87, No. 12, pp. 884-894.
Martinell, J. “Calculation for Approximate Number of Embodiments in a Percent Identity Claim (Peptides),” Nov. 17, 1999.
Adamson, D. et al. “Significant Telomere Shortening in Childhood Leukemia”,Cancer Genet. Cytogenet, 1992; pp. 204-206, vol. 61.
Autexier, Chantal, et al., Telomerase and cancer: revisiting the telomere hypothesis; Trends in Biochemical Sciences, 1996, pp. 387-391, vol. 10, No. 21.
Avilion, A., “Characterization and expression of human telomerase,” Dissertation Abstracts International, 1996, pp. 5930-B, vol. 56, No. 11.
Baringa, Marcia, “The Telomerase Picture Fills In”,Science, Apr. 25, 1997; pp. 528-529, vol. 276.
Chiu, et al. “Replicative senescence and cell immortality: the role of telomeres and telomerase (44075)”,Proc. Soc. Exp. Bio. Med., 1997, pp. 99-106, vol. 214.
Chong, L. et al. “A Human Telomeric Protein”,Science, Dec. 1995, pp. 1663-1667, vol. 270.
Collins, Kathleen, “Structure and function of telomerase”, Current Opinion in Cell Biology, 1996, pp. 374-380, vol. 8.
Counter, C. et al. “Telomerase Activity in Normal Leukocytes and in Hematologic Malignancies”Blood; May 1, 1995; pp. 2315-2320, vol. 85, No. 9.
Counter, C. et al, “Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity”,The EMBO Journal; 1992, pp. 1921-1929, vol. 11; No. 5, Oxford University Press.
De Lange, T. et al. “Structure and Variability of Human Chromosome Ends”;Molecular and Cellular Biology; Feb. 1990; pp. 518-527, vol. 10, No. 2.
Flavell, R. & Mathias, R. “Prospects for transforming monocot crop plants”,Nature, Jan. 12, 1984, pp. 108-109, vol. 307.
Freshney,Culture of Animal Cells. A Manual Basic Technique, p. 4, Alan R. Liss, Inc. New York, 1983.
Genbank Accession No. A46242; Sep. 21, 1993.
Genbank Accession No. L38903; Jan. 30, 1995.
Genbank Accession No. Q06163; Nov. 1, 1995.
Genbank Accession No. S39696; Oct. 7, 1994.
Genbank Accession No. S53396; May 5, 1995.
GenBank Accession No. U95964: May 5, 1997.
GenBank Accession No. W70315; Jun. 19, 1996.
Glaser, P. et al. “Bacillus subtilisgenome project: cloning and sequencing of the 97 kb region from 325° to 333°”Molecular Microbiology, 1993, pp. 371-384, vol. 10, No. 2.
Goodman, R. et al. “Gene Transfer in Crop Improvement”, Science, Apr. 3, 1997, pp. 48-54, vol. 236.
Greider, C. “Telomeres, Telomerase and Senescence”;BioEssays; 1990: pp. 363-369, vol. 12, No. 8.
Harley, C. “Telomere loss: Mitotic clock or genetic time bomb?”Mutation Research; 1991; pp. 271-282, vol. 256, Elsevier Science Publishers.
Harley, C. & Villeponteau, B. “Telomeres and telomerase in aging and cancer”Current Opinion in Genetics and Development; 1995, pp. 249-255, vol. 5.
Harley, C. et al. “Telomeres shorten during ageing of human fibroblasts”,Nature, May 31, 1990; pp. 458-460, vol. 345.
Hastie, N. et al. “Telomere reduction in human colorectal carcinoma and with ageing”,Nature, Aug. 30, 1990, pp. 866-868, vol. 346.
Healy, K. C. “Telomere dynamics and telomerase activation in tumor progression: prospects for prognosis and therapy”Oncol. Res., 1995, pp. 121-130, vol. 7.
Henderson, C. Cancer genetics gene regulates telomerase resulting in death of cancer cells;Gene Therapy Weekly; Sep. 11, 1995.
Hiyama, E. et. al. “Correlating telomerase activity levels with human neuroblastoma outcomes”;Nature Medicine; Mar. 3, 1995; pp. 249-255, vol. 1, No. 3.
Holtzmann, K. et al. “Telomeric Associations and Loss of Telomeric DNA Repeats in Renal Tumors”,Genes, Chromosomes&Cancer, 1993, pp. 178-181, vol. 6.
Jähne, A. et al. “Genetic Engineering of Cereal Crop Plants: A Review”, Euphytica, 1995, pp. 35-44, vol. 85, Kluwer Academic Publishers, Netherlands.
Jolliffe, L.K. “Humanized antibodies: enhancing therapeutic utility through antibody engineering”,Int. Rev. Immunol., 1993, pp. 241-250, vol. 10.
Kim, N. et al. “Specific Association of Human Telomerase Activity with Immortal Cells and Cancer”,Science, Dec. 23, 1994, pp. 2011-2014, vol. 266.
Klingelhutz, A. et al. “Restoration of Telomeres in Human Papillomavirus- Immortalized Human Anogenital Epithelial Cells”;Molecular and Cellular Biology; Feb. 1994, pp. 961-969, vol. 14, No. 2.
Lewis, A. & Crowe, J.S. “Generation of humanized monoclonal antibodies by ‘best fit’ framework selection and recombinant polymerase chain reaction”,Year Immuno

Affiliated with

Also associated with

Rating

Nucleic acids encoding human telomerase reverse... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nucleic acids encoding human telomerase reverse..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acids encoding human telomerase reverse... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3849886